Conference being held October 10-12, 2023 in Carlsbad, California
MONTRÉAL, September 18, 2023 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that David Millette, CEO, will present in person at the annual Cell & Gene Meeting on the Mesa conference to be held on October 10-12, 2023, at the Park Hyatt Aviara Resort in Carlsbad, California.
The presentation will provide an overview of the company, including:
- its proprietary technologies in cell and gene therapy, including molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and rejuvenation of HSCs;
- clinical results and updates for UM171-expanded Cell Therapy, which is now in late-stage development and part of Cordex Biologics Inc., an ExCellThera company; and
- its EnhanceTM cell expansion and rejuvenation platform for cell and gene therapies.
Event: ExCellThera Corporate Presentation Date: Tuesday, October 10, 2023 Time: 10:00 AM Pacific Time (1:00 PM Eastern Time) Location: Ecolab Life Sciences Ballroom, Park Hyatt Aviara Resort, Carlsbad, CA, and livestream
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This year’s meeting is expected to attract over 2,000 attendees and enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the sector.
About UM171-expanded Cell Therapy and Cordex Biologics
Cordex Biologics Inc., an ExCellThera company, develops UM171-expanded Cell Therapy and other UM171-expanded cord blood-based cell therapies. UM171-expanded Cell Therapy has been evaluated in over 100 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171-expanded Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. For additional information, visit www.cordexbio.com, and follow us on LinkedIn.
UM171-expanded Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority.
ExCellThera is a world leader in blood stem cell expansion and rejuvenation. ExCellThera’s proprietary EnhanceTM platform for cell expansion and rejuvenation is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharma companies and institutions to help them develop best-in-class cell and gene therapies by leveraging the technologies and processes that form the EnhanceTM platform, including proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and rejuvenation of HSCs. For additional information, visit www.excellthera.com, and follow us on LinkedIn.